Replimune Group Inc 2025年季度报告

FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJune30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number001-38596 REPLIMUNE GROUP, INC.(Exact name of registrant as specified in its charter) 500 Unicorn Park Drive Suite 303 WoburnMA01801(Address of principal executive offices)(Zip Code)(781)222-9600(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15 (d)of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subjectto such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ The number of shares of the registrant’s Common Stock, par value $0.001 per share, outstanding as of August4, 2025 was78,055,846. REPLIMUNE GROUP,INC. FORM10-QTable of ContentsPageNo.PART I FINANCIAL INFORMATION3Item 1.Condensed Consolidated Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations4Condensed Consolidated Statements of Comprehensive Loss5Condensed Consolidated Statements of Stockholders’ Equity6Condensed Consolidated Statements of Cash Flows7Notes to Unaudited Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures About Market Risk36Item 4.Controls and Procedures37PART II OTHER INFORMATION39Item 1.Legal Proceedings39Item 1A.Risk Factors39Item 2.Unregistered Sales of Equity Securities and Use of Proceeds77Item 3.Defaults Upon Senior Securities77Item 4.Mine Safety Disclosure77Item 5.Other Information77Item 6.Exhibits77SIGNATURES79 PART I-FINANCIAL INFORMATION REPLIMUNE GROUP,INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands, except share and per share amounts)(Unaudited) June 30, 2025March 31, 2025 REPLIMUNE GROUP,INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Amounts in thousands, except share and per share amounts)(Unaudited) REPLIMUNE GROUP,INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(Amounts in thousands)(Unaudited) Three Months Ended June 30,20252024Net loss$(86,693)$(53,772)Other comprehensive loss:Foreign currency translation loss(938)(432)Net unrealized loss on short-term investments, net of tax of $0(269)(99)Comprehensive loss$(87,900)$(54,303) The accompanying notes are an integral part of these condensed consolidated financial statements. REPLIMUNE GROUP,INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Amounts in thousands)(Unaudited) REPLIMUNE GROUP,INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Dollars in thousands, except share and per share amounts)(Unaudited) 1.Nature of the business Replimune Group,Inc. (the “Company”) is a clinical-stage biotechnology company with the mission to transform cancer treatment bypioneering the development of a novel portfolio of oncolytic immunotherapies. The Company's proprietary oncolytic immunotherapy productcandidates are intended to maximally activate the immune system against cancer. Replimune Group,Inc., whose predecessor was founded in2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (“Replimune UK”); Replimune,Inc.(“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to,development by competitors of new technological innovatio